drugset / Trial / NCT03953196

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

NCT03953196

Phase 0 Completed 48 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to characterize the immune response in vivo using approved vaccines and antigen challenges, as well as a skin wounding challenge to stimulate the immune system.

Timeline

Start
2019-04-08
Primary completion
2019-12-26
Completion
2019-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Candin Other / unclassified 0.1 ml Other
Subject IMVAMUNE Vaccine 0.5 ml Subcutaneous
Subject LPS Unknown 1 ng Intravenous
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.